Cover Image

Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Masashi Hasebe, Chen‐Yang Su, Yamato Keidai, Hiroto Minamino, Daisuke Yabe, Nobuya Inagaki, Satoshi Yoshiji
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cardiovascular and kidney benefits of GLP ‐1 receptor agonists across large randomized placebo‐controlled trials
by: Satoshi Yoshiji, et al.
Published: (2025)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
by: Stephanie L. Samuels, et al.
Published: (2024)

Impact of COVID ‐19 restrictions and their relaxation on body composition and glycemic control in individuals with glucose intolerance in Japan: A single‐center observational study
by: Ami Kobayashi, et al.
Published: (2026)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
by: David C. Klonoff, et al.
Published: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
by: Darren Lau, et al.
Published: (2024)

Expanding the discussion on airway management with glucagon‐like peptide‐1 receptor agonist use
by: Jenny E. Pennycuff, et al.
Published: (2025)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
by: Jessica Van Laren, et al.
Published: (2026)

Gastric ultrasound and mitigating risk of glucagon‐like peptide‐1 receptor agonists: a reply
by: Peter C.‐A. Kam, et al.
Published: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
by: Yunwen Xu, et al.
Published: (2025)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
by: Iskandar Idris
Published: (2024)

Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
by: Michael G. Buontempo, et al.
Published: (2025)

Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis
by: Gianmaria Salvio, et al.
Published: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
by: Karen L. Jones, et al.
Published: (2024)

Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon‐like peptide‐1 agonists
by: Naadir Jamal, et al.
Published: (2024)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2024)

Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
by: Sara Berg, et al.
Published: (2025)

The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
by: Yu Zhang, et al.
Published: (2024)

Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia
by: Kaori Ikeda, et al.
Published: (2025)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
by: Filip K. Knop, et al.
Published: (2024)

Should diabetes be managed with tight HbA1c control?
by: Tripdatabase
Published: (2026)

Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
by: Mehmet Kanbay, et al.
Published: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
by: Fu‐Shun Yen, et al.
Published: (2025)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
by: Aakash Desai, et al.
Published: (2024)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
by: Irl B. Hirsch, et al.
Published: (2024)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes
by: Yu‐Ting Yu, et al.
Published: (2026)

Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
by: Jason Zupec, et al.
Published: (2025)

The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
by: Victoria Wen Wei Ng, et al.
Published: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
by: Ruoyang Jiao, et al.
Published: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
by: Tae Hyeon Kim, et al.
Published: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
by: Jason M. Samuels, et al.
Published: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
by: Julio Rosenstock, et al.
Published: (2025)

From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model
by: Rolien Bosch, et al.
Published: (2025)

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
by: Kariem El‐Boghdadly, et al.
Published: (2025)

A patient choice‐driven lifestyle intervention lowers HbA1c in type 2 diabetes: A feasibility study
by: Nathan R. Weeldreyer, et al.
Published: (2025)

Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐ O trial
by: Hertzel C. Gerstein, et al.
Published: (2024)

Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
by: Deep Dutta, et al.
Published: (2024)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
by: Yi‐Chang Chou, et al.
Published: (2025)

Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis
by: Pedro Robson Costa Passos, et al.
Published: (2024)

Depression following the initiation of glucagon‐like‐peptide‐1 receptor agonist therapy: A multinational self‐controlled case series study
by: Vincent Ka Chun Yan, et al.
Published: (2026)

The fasting and the furious: reconciling fasting guidelines with glucagon‐like peptide‐1 receptor agonists, ‘Sip‐til‐Send’ policies and gastric ultrasound
by: N. S. Sidhu, et al.
Published: (2025)